Pharming Group N.V annual shares outstanding
2018
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V Shares Outstanding History (PHAR)
Pharming Group N.V reported 701.7M shares outstanding at the end of fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 701.7M | 21.4M | +3.14% |
| 2024 | 2024-12-31 | 680.3M | 9.2M | +1.38% |
| 2023 | 2023-12-31 | 671.1M | 14.7M | +2.24% |
| 2022 | 2022-12-31 | 656.3M | 7.6M | +1.17% |
| 2021 | 2021-12-31 | 648.7M | 9.9M | +1.55% |
| 2020 | 2020-12-31 | 638.8M | 7.5M | +1.19% |
| 2019 | 2019-12-31 | 631.3M | 9.8M | +1.58% |
| 2018 | 2018-12-31 | 621.5M | — | — |
Pharming Group N.V quarterly shares outstanding
Q4.20
Q4.21
Q4.22
Q4.23
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 707.8M | 22.6M | +3.30% |
| Q1 2026 | 2026-03-31 | 706.3M | — | — |
| Q4 2025 | 2025-12-31 | 701.7M | 21.4M | +3.14% |
| Q3 2025 | 2025-09-30 | 696.7M | — | — |
| Q2 2025 | 2025-06-30 | 685.1M | — | — |
| Q4 2024 | 2024-12-31 | 680.3M | 9.2M | +1.38% |
| Q4 2023 | 2023-12-31 | 671.1M | 14.7M | +2.24% |
| Q4 2022 | 2022-12-31 | 656.3M | 7.6M | +1.17% |
| Q4 2021 | 2021-12-31 | 648.7M | 9.9M | +1.55% |
| Q4 2020 | 2020-12-31 | 638.8M | — | — |
Pharming Group N.V shares outstanding trends
Over the last five fiscal years, Pharming Group N.V's shares outstanding moved from 638.8M to 701.7M, a change of 62.9M. The latest reported quarter, Q2 2026, shows 707.8M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming secures priority review for lower-dose pediatric Joenja
Pharming ($PHAR) said the FDA accepted its supplemental application for a lower-dose Joenja formulation and granted priority review. The proposed expansion addresses patients aged four and older with activated PI3K delta syndrome who weigh ...
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...
